Award

Ask AI about this notice

Summarise, research or assess it with AI

View Markdown

Share this notice

Send this contract to a colleague

NP49425 Generic and Biosimilar Transition Medicines

The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

This public procurement record has 4 releases in its history.

AwardUpdate

30 Mar 2026 at 01:00

OJEU - F20 - Modification Notice
Award

19 Dec 2025 at 00:00

OJEU - F3 - Contract Award Notice
TenderUpdate

04 Sep 2025 at 01:00

OJEU - F14 - Corrigendum
Tender

21 Aug 2025 at 01:00

OJEU - F2 - Contract Notice
Summary of the contracting process

The Common Services Agency, widely known as NHS National Services Scotland (NSS), has completed the tender process for the "NP49425 Generic and Biosimilar Transition Medicines" procurement, aimed at supplying these medications to NHS Scotland. The procurement falls under the goods category, specifically classified under the CPV code 33600000, indicating pharmaceutical products. The location for delivery spans all entities constituted under the National Health Service (Scotland) Act 1978 within the UK region UKM. The procurement process followed an open procedure method, marked by key dates, including a start date for the award period on 18 December 2025, and the tender submission closing on 22 September 2025. The associated contract carries a total estimated value of GBP 234,969,011, to be executed over a variable duration across individual product lines, with provisions for optional extensions.

This tender presents a significant opportunity for large-scale pharmaceutical suppliers, particularly those specialising in generic and biosimilar medicines, to expand their operations by partnering with a major public health authority in Scotland. The framework agreement, structuring the tender into multiple lots for different medicines, such as cytokine modulators and cancer medicines, provides diverse entry points for suppliers. Companies with strong supply chain capabilities and compliance with quality assurances like BS EN ISO 9001 and MHRA guidelines stand well-positioned to benefit from this substantial procurement. The involvement of community benefit initiatives further enhances opportunities, allowing suppliers to engage more deeply with local communities through the NHS Scotland's Community Benefits Gateway.

How relevant is this notice?

Notice Information

Notice Title

NP49425 Generic and Biosimilar Transition Medicines

Notice Description

Supply of generic and biosimilar transition medicines to NHS Scotland.

Lot Information

Cytokine Modulators (Golimumab, Tocilizumab, and Etanercept)

Supply of generic cand biosimilar transition medicines to NHS Scotland. The Authority has awarded this Lot as an unranked multi supplier Framework Agreement per line to six (6) Framework Participants. Full details of Goods and volumes can be found within the ITT (Invitation to Tender) documents.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of thirty-five (35) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Cytokine Modulators (Omalizumab)

Supply of cytokine modulators (omalizumab) to NHS Scotland. The Authority has awarded this Lot as an unranked multi supplier Framework Agreement per product line.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of thirty-five (35) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Gastrointestinal, Endocrine, Blood, and Multiple Sclerosis Medicines

Supply of gastrointestinal, endocrine, blood, and multiple sclerosis medicines to NHS Scotland. The Authority has awarded this Lot as a ranked multi supplier Framework Agreement per product line.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of thirty (30) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Denosumab (Osteoporosis) and Ferric Carboxymaltose

Supply of denosumab (osteoporosis) and ferric carboxymaltose to NHS Scotland. The Authority has awarded this Lot as an unranked multi supplier Framework Agreement per product line.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of thirty (30) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Apremilast

Supply of apremilast to NHS Scotland. The Authority has awarded this Lot as a ranked multi supplier Framework Agreement per product line.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of twenty-seven (27) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Cardiovascular and Respiratory Medicines

Supply of cardiovascular and respiratory medicines to NHS Scotland. The Authority has awarded this Lot as a ranked multi supplier Framework Agreement per product line.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of twenty-one (21) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Nintedanib

Supply of nintedanib to NHS Scotland. The Authority has awarded this Lot as a ranked multi supplier Framework Agreement per product line.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of twenty-one (21) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Cancer Medicines (Group 1)

Supply of cancer medicines (group 1) to NHS Scotland. The Authority has awarded this Lot as a ranked multi supplier Framework Agreement per product line.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of thirty-six (36) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Cancer Medicines (Group 2)

Supply of cancer medicines (group 2) to NHS Scotland. The Authority has awarded this Lot as an unranked multi supplier Framework Agreement per product line.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of thirty-six (36) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Psychiatry and Neurology Medicines

Supply of psychiatry and neurology medicines to NHS Scotland. The Authority has awarded this Lot as a ranked multi supplier Framework Agreement per product line.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of seventeen (17) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-r6ebe6-0000807501
Publication Source
Public Contracts Scotland
Latest Notice
https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=MAR552801
Current Stage
Award
All Stages
Tender, Award

Procurement Classification

Notice Type
OJEU - F20 - Modification Notice
Procurement Type
Framework
Procurement Category
Goods
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
Not specified
Awardee Scale
Large

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products

CPV Codes

33600000 - Pharmaceutical products

Notice Value(s)

Tender Value
£234,969,011 £100M-£1B
Lots Value
£234,969,011 £100M-£1B
Awards Value
Not specified
Contracts Value
£128,207,480 £100M-£1B

Notice Dates

Publication Date
30 Mar 20265 months ago
Submission Deadline
22 Sep 2025Expired
Future Notice Date
Not specified
Award Date
18 Dec 20258 months ago
Contract Period
1 Feb 2026 - 30 Sep 2028 2-3 years
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Complete
Awards Status
Not Specified
Contracts Status
Active

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
EDINBURGH
Postcode
EH12 9EB
Postcode Area
Edinburgh
Country
Scotland
Major Region (ITL 1)
TLM Scotland
Basic Region (ITL 2)
TLM1 East Central Scotland
Small Region (ITL 3)
TLM13 City of Edinburgh
Delivery Location
TLM Scotland
Local Authority
City of Edinburgh
Electoral Ward
Drum Brae/Gyle
Westminster Constituency
Edinburgh South West

Supplier Information

Number of Suppliers
39
Supplier Names

AOP Orphan Ltd

Accord Healthcare Ltd

Amarox Limited

Amgen Ltd

Biocon Pharma UK Ltd

Brown and Burk

CST Pharma Ltd

Celix Pharma Ltd.

Celltrion Healthcare United Kingdom Limited

Chiesi Limited

Chiesi Ltd

Dr Falk Pharma UK Ltd

Dr Reddy's Laboratories (UK) Ltd

Ferring Pharmaceuticals Limited

Fresenius Kabi

Fresenius Kabi Ltd

Gedeon Richter UK Ltd

Glenmark Pharmaceuticals Europe Ltd

Janssen-Cilag Ltd

Lupin Healthcare UK Ltd

MSN Labs

Mercury Pharma Group

Mercury Pharmaceuticals Limited

Perennial Pharma Ltd

Pfizer

Roche Products Ltd

SERB SA

STADA UK - Thornton & Ross

Samsung Bioepis Ltd

Sandoz

Takeda UK Limited

Teva UK Ltd

Theramex HQ UK Ltd

Viatris UK Healthcare Ltd

Vifor Pharma UK Limited

Wockhardt UK Limited

Zentiva Pharma UK Ltd

Zentiva UK

Zydus Pharmaceuticals UK Ltd

Further Information

Notice Documents

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...